post-template-default,single,single-post,postid-1432,single-format-standard,strata-core-1.1.1,strata-child-theme-ver-1.0.0,strata-theme-ver-3.4,ajax_fade,page_not_loaded,wpb-js-composer js-comp-ver-7.2,vc_responsive

Boehringer Ingelheim’s continued Expansion

11:27 26 January in Sectors

The Bracknell based pharmaceutical supplier, Boehringer Ingelheim UK Ltd has underlined its commitment to the UK and Thames Valley with the refurbishment and expansion of its offices.

Boehringer Ingelheim (BI) provides treatments for a range of long term and acute diseases and consistently reinvests over 20% of their net sales in researching new and innovative medicines in areas of high unmet need. This investment in R&D has been the foundation of BI’s success and has helped them discover and develop new medicines to improve lives for humans and animals.

The company moved to their present location in Bracknell in the 1970’s and refurbished it during the 1980’s and 1990’s. Now, no-longer new, and operating at near capacity, BI decided that the present building would need to be extended to allow for capacity to expand, as well as to provide a substantial remodelling of the office layout to aid efficient working and provide a state of the art working environment.

BI approved a (£6m+) redevelopment of the site  involving a two-storey extension comprising ground floor training rooms and other facilities with first floor meeting rooms.

UKTI maintained contact with UK management as these plans evolved and liaised with respective local authority and delivery partners as permission was granted in the early part of 2015.  UK Government looked to further cement its relationship with BI by a visit by the Life Sciences Minister, George Freeman, MP with Volker Barkmann, Head of Stakeholder Management at BI, during a trip to Germany.  The Minister was keen to develop his understanding of BI’s investment in the UK and the interaction with UK assets and expertise.

UKTI’s local delivery partner, Thames Valley Chamber, supported BI’s application and helped BI’s engagement with senior officials and the economic development team within the local authority throughout the process.

“Boehringer Ingelheim has long been regarded as a leading employer, and this investment is good news for the UK Life Science sector and Bracknell, as well as its talented workforce. The investment supports BI UK’s role as a leading clinical development and health economics centre for the BI group. Andy Hook, Sector Investment Manager, UKTI Investment Services.

“The decision to invest in the local area underlines Boehringer Ingelheim’s commitment to the UK, to its people and facilities and to improving the health and quality of patients’ lives.” Alan Sumner, Deputy Director of Communications, Boehringer Ingelheim.

Step forward to the 13th November 2015, a date that marked the official commencement of construction works to expand the offices, with a ground breaking ceremony with local dignitaries and Boehringer Ingelheim UK & Ireland’s Managing Director, Professor Klaus Dugi and the Main Contractor, Herbert H Drew & Son.

Boehringer Ingelheim UK & Ireland Managing Director, Professor Klaus Dugi commented: “This is a significant milestone for Boehringer Ingelheim. We aim to create the best possible working environment for our staff and are always looking at ways to improve on the service and commitment levels we deliver to our patients. We are looking forward to having the team all under one roof.   We wish Drew all the best for a successful and timely contract.”

Herbert H Drew & Son Contracts Director, Paul Gillard commented: “We are delighted to be working in partnership with Boehringer Ingelheim to deliver these new and improved facilities.”